Overview

Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Status:
Completed

Trial end date:
2003-03-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have refractory or recurrent acute myeloid leukemia or chronic myelogenous leukemia.

Phase:

Phase 1

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Camptothecin
Cytarabine
Irinotecan